|Director of the Advanced Research Projects Agency for Health 22|
|Assumed office |
|Appointed by||Joe Biden|
|Preceded by||Position established|
|Born||1976/1977 (age 45–46)|
|Education||Georgia Institute of Technology (BS, MS, PhD)|
From 2003 to 2006, Wegrzyn worked as a post-doctoral research fellow at the European Molecular Biology Laboratory. From 2006 to 2008, she worked as the assay development group leader for Adlyfe, a biotechnology company based in Quebec. In 2009, she was a senior scientist at Meso Scale Discovery and in 2012, she was a fellow at the Johns Hopkins Center for Health Security. From 2009 to 2016, she worked as a senior lead technologist at Booz Allen Hamilton. From 2016 to 2020, she served as a program manager in the Biological Technologies Office of DARPA, where she specialized in synthetic biology and biosecurity. Since 2018, she has been a senior advisor to the Nuclear Threat Initiative. In 2020, she joined Ginkgo Bioworks as vice president of business development.
- ^ Kaiser, Jocelyn (September 12, 2022). "Biden's New Biomedical Innovation Agency Gets Its First Director". Science. Retrieved September 22, 2022.
- ^ "President Biden Announces Intent to Appoint Dr. Renee Wegrzyn as Inaugural Director of Advanced Research Projects Agency for Health (ARPA-H)". The White House. 2022-09-12. Retrieved 2022-09-12.
- ^ "DARPA Forward | Dr. Renee Wegrzyn". forward.darpa.mil. Retrieved 2022-09-12.
- ^ "Biden appoints former government scientist as first leader of ARPA-H". STAT. 2022-09-12. Retrieved 2022-09-12.
- ^ Stolberg, Sheryl Gay (2022-09-12). "Biden Picks Biotech Executive to Lead New Biomedical Research Agency". The New York Times. ISSN 0362-4331. Retrieved 2022-09-12.